{
    "clinical_study": {
        "@rank": "132810", 
        "arm_group": [
            {
                "arm_group_label": "Renal Denervation Group", 
                "arm_group_type": "Other", 
                "description": "Subjects receiving renal denervation procedure."
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects not receiving renal denervation procedure.\nSubjects are randomized in a 3:1 ratio to either Treatment Group or Control Group."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical investigation is to determine the effects of renal sympathetic\n      denervation on the insulin resistance, muscle sympathetic nerve activity and blood pressure\n      in patients with metabolic syndrome and associated uncontrolled hypertension."
        }, 
        "brief_title": "Renal Sympathetic Denervation for Treatment of Metabolic Syndrome Associated Hypertension (Metabolic Syndrome Study)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metabolic Syndrome", 
            "Uncontrolled Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Metabolic Syndrome X"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with office blood pressure \u2265140/90 mmHg and 24-hour ambulatory blood pressure\n             \u2265130/80 mmHg at Enrollment despite treatment with two drugs at maximum tolerated\n             doses\n\n          -  Patient with a fasting glucose \u2265100 mg/dL (\u22655.6 mmol/L) at Enrollment\n\n          -  Patient with a waist circumference \u2265102 cm (\u226540 inches) for male or \u226588 cm (\u226535\n             inches) for female at Enrollment\n\n          -  Patient with any of the other metabolic syndrome diagnostic criteria listed as\n             follows at Enrollment\n\n               -  Triglycerides \u2265150 mg/dL (\u22651.7 mmol/L) or on drug treatment for elevated\n                  triglycerides\n\n               -  High density lipid cholesterol (HDL-C) <40 mg/dL (<1.03 mmol/L) for male or <50\n                  mg/dL (<1.30 mmol/L) for female or on drug treatment for reduced HDL-C\n\n          -  Patient is \u226518 and \u226480 years old\n\n          -  Patient must be able and willing to provide written informed consent to participate\n             in this clinical investigation\n\n          -  Patient must be able and willing to comply with the required follow-up schedule\n\n        Exclusion Criteria:\n\n          -  Patient with resistant hypertension or secondary hypertension\n\n          -  Patient with type I diabetes mellitus or type II diabetes mellitus requiring insulin\n             therapy\n\n          -  Patient with prior renal angioplasty, renal denervation, indwelling renal stents\n             and/or aortic stent grafts\n\n          -  Patient with renal arteries <4.0 mm in diameter\n\n          -  Patient with significant renovascular abnormalities (such as renal artery stenosis\n             >30%)\n\n          -  Patient with an estimated glomerular filtration rate (eGFR) of <45 mL/min per 1.73 m2\n             using the Modified Diet in Renal Disease (MDRD) formula\n\n          -  Patient with hemodynamically significant valvular heart disease, as determined by\n             Study Investigator\n\n          -  Patient has had a myocardial infarction, unstable angina pectoris or cerebrovascular\n             accident less than 180 days at Enrollment or is expected to have cardiovascular\n             intervention within the next 180 days\n\n          -  Patient is in chronic atrial fibrillation/flutter or with severe conduction\n             abnormalities or with an implantable cardioverter defibrillator (ICD) or pacemaker\n             whose settings cannot allow for radiofrequency (RF) energy delivery\n\n          -  Patient is currently being treated with drugs that cause salt retention (such as\n             systemic corticosteroids or fludrocortisone)\n\n          -  Patient with an active systemic infection or blood-clotting abnormalities\n\n          -  Patient is pregnant or of childbearing potential and is not using adequate\n             contraceptive methods or nursing\n\n          -  Patient is participating in another clinical investigation\n\n          -  Patient has a life expectancy less than 12 months, as determined by Study\n             Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911078", 
            "org_study_id": "CI-12-079-EU-RD"
        }, 
        "intervention": [
            {
                "arm_group_label": "Renal Denervation Group", 
                "description": "Renal artery ablation with the EnligHTN\u2122 Renal Denervation System.", 
                "intervention_name": "Renal Denervation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Renal Denervation Group", 
                "intervention_name": "EnligHTN\u2122 Renal Denervation System.", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metabolic syndrome", 
            "Uncontrolled hypertension", 
            "Renal denervation", 
            "Renal artery"
        ], 
        "lastchanged_date": "July 29, 2013", 
        "number_of_arms": "2", 
        "official_title": "Renal Sympathetic Denervation for Treatment of Metabolic Syndrome Associated Hypertension (Metabolic Syndrome Study)", 
        "overall_contact": {
            "email": "elau@sjm.com", 
            "last_name": "Elizabeth Lau, PhD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the effects of renal sympathetic denervation on the insulin resistance (determined by the Homeostasis Model Assessment - Insulin Resistance method) at 3 months after renal denervation", 
            "measure": "Change in insulin resistance from baseline to 3 months after renal denervation", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911078"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the effects of renal sympathetic denervation on the insulin resistance long-term (12 months after renal denervation).", 
                "measure": "Change in insulin resistance from baseline to 12 months after renal denervation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }, 
            {
                "description": "To determine the effects of renal sympathetic denervation on the MSNA at 3 months and 12 months after renal denervation", 
                "measure": "Change in muscle sympathetic nerve activity (MSNA) from baseline to 3 months and 12 months after renal denervation", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 3 and Month 12"
            }, 
            {
                "description": "To determine the effects of renal sympathetic denervation on the blood pressure long-term (12 months after renal denervation).", 
                "measure": "Change in blood pressure from baseline to 12 months after renal denervation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}